CDK9-IN-53
CDK9-IN-53 is a potent and selective CDK9 inhibitor with a Ki of 7 nM and an IC50 of 14 nM against CDK9/Cyclin T1. CDK9-IN-53 achieves highly selective inhibition by competitively binding to the ATP pocket of CDK9, thereby blocking RNAPII transcription and downregulating the anti-apoptotic protein Mcl-1, ultimately triggering Caspase-dependent apoptosis in cancer cells. CDK9-IN-53 can be used for research on chronic lymphocytic leukemia.
For research use only. We do not sell to patients.
- CAS No.: 1421340-50-2
- Formula: C21H24N8S
- Molecular Weight:420.54
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Caspase Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
CDK9 7 nM (Ki) |
CDK9/cyclinT1 14 nM (IC50) |
Caspase-3 |
Mcl-1 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-116 | GI50 |
0.420 μM
|
Antiproliferative activity against human HCT-116 (p53wt, pRb+) cells assessed as GI50 by MTT assay after 48 hrs.
Antiproliferative activity against human HCT-116 (p53wt, pRb+) cells assessed as GI50 by MTT assay after 48 hrs.
|
23301767 |
| HCT-116 | GI50 |
0.780 μM
|
Antiproliferative activity against human HCT-116 (p53null) cells assessed as GI50 by MTT assay after 48 hrs.
Antiproliferative activity against human HCT-116 (p53null) cells assessed as GI50 by MTT assay after 48 hrs.
|
23301767 |
| HCC 2998 | GI50 |
0.385 μM
|
Antiproliferative activity against human HCC 2998 (p53wt, pRb+) cells assessed as GI50 by MTT assay after 48 hrs.
Antiproliferative activity against human HCC 2998 (p53wt, pRb+) cells assessed as GI50 by MTT assay after 48 hrs.
|
23301767 |
| MCF7 | GI50 |
0.690 μM
|
Antiproliferative activity against human MCF-7 (p53wt, pRb+, ER+) cells assessed as GI50 by MTT assay after 48 hrs.
Antiproliferative activity against human MCF-7 (p53wt, pRb+, ER+) cells assessed as GI50 by MTT assay after 48 hrs.
|
23301767 |
| MDA-MB-468 | GI50 |
0.402 μM
|
Antiproliferative activity against human MDA-MB468 (p53mut, pRb−, ER−) cells assessed as GI50 by MTT assay after 48 hrs.
Antiproliferative activity against human MDA-MB468 (p53mut, pRb−, ER−) cells assessed as GI50 by MTT assay after 48 hrs.
|
23301767 |
| A2780 | GI50 |
0.320 μM
|
Antiproliferative activity against human A2780 cells assessed as GI50 by MTT assay after 48 hrs.
Antiproliferative activity against human A2780 cells assessed as GI50 by MTT assay after 48 hrs.
|
23301767 |
| HeLa | GI50 |
0.630 μM
|
Antiproliferative activity against human HeLa cells assessed as GI50 by MTT assay after 48 hrs.
Antiproliferative activity against human HeLa cells assessed as GI50 by MTT assay after 48 hrs.
|
23301767 |
| TK-10 | GI50 |
0.747 μM
|
Antiproliferative activity against human TK 10 cells assessed as GI50 by MTT assay after 48 hrs.
Antiproliferative activity against human TK 10 cells assessed as GI50 by MTT assay after 48 hrs.
|
23301767 |
| PANC-1 | GI50 |
0.590 μM
|
Antiproliferative activity against human PANC-1 cells assessed as GI50 by MTT assay after 48 hrs.
Antiproliferative activity against human PANC-1 cells assessed as GI50 by MTT assay after 48 hrs.
|
23301767 |
| HMEC-1 | GI50 |
3.120 μM
|
Antiproliferative activity against human HMEC-1 cells assessed as GI50 by MTT assay after 48 hrs.
Antiproliferative activity against human HMEC-1 cells assessed as GI50 by MTT assay after 48 hrs.
|
23301767 |
| MRC5 | GI50 |
5.960 μM
|
Antiproliferative activity against human MRC-5 cells assessed as GI50 by MTT assay after 48 hrs.
Antiproliferative activity against human MRC-5 cells assessed as GI50 by MTT assay after 48 hrs.
|
23301767 |
| WI-38 | GI50 |
5.490 μM
|
Antiproliferative activity against human WI-38 cells assessed as GI50 by MTT assay after 48 hrs.
Antiproliferative activity against human WI-38 cells assessed as GI50 by MTT assay after 48 hrs.
|
23301767 |
| A2780 | GI50 |
0.493 μM
|
Antiproliferative activity against human A2780 cells assessed as GI50 by MTT assay after 24 hrs.
Antiproliferative activity against human A2780 cells assessed as GI50 by MTT assay after 24 hrs.
|
23301767 |
| A2780 | GI50 |
0.288 μM
|
Antiproliferative activity against human A2780 cells assessed as GI50 by MTT assay after 72 hrs.
Antiproliferative activity against human A2780 cells assessed as GI50 by MTT assay after 72 hrs.
|
23301767 |
| MRC5 | GI50 |
6.250 μM
|
Antiproliferative activity against human MRC-5 cells assessed as GI50 by MTT assay after 24 hrs.
Antiproliferative activity against human MRC-5 cells assessed as GI50 by MTT assay after 24 hrs.
|
23301767 |
| MRC5 | GI50 |
5.670 μM
|
Antiproliferative activity against human MRC-5 cells assessed as GI50 by MTT assay after 72 hrs.
Antiproliferative activity against human MRC-5 cells assessed as GI50 by MTT assay after 72 hrs.
|
23301767 |
| HMEC-1 | GI50 |
7.500 μM
|
Antiproliferative activity against human HMEC-1 cells assessed as GI50 by MTT assay after 24 hrs.
Antiproliferative activity against human HMEC-1 cells assessed as GI50 by MTT assay after 24 hrs.
|
23301767 |
| HMEC-1 | GI50 |
4.500 μM
|
Antiproliferative activity against human HMEC-1 cells assessed as GI50 by MTT assay after 72 hrs.
Antiproliferative activity against human HMEC-1 cells assessed as GI50 by MTT assay after 72 hrs.
|
23301767 |
In Vitro
CDK9-IN-53 (compound 12u) (48 h) inhibited the proliferation of HCT-116, A2780, MCF-7, and other tumor cell lines with GI50 values of 0.320-0.780 μM, whereas non-transformed HMEC-1, MRC-5, and WI-38 cells were less sensitive with GI50 values of 3.120-5.960 μM[1].
CDK9-IN-53 (GI50-10 x GI50; 24-48 h) significantly activates Caspase-3 activity, induces apoptosis in a dose-dependent manner, causes G2/M phase cell cycle arrest, inhibits RNAPII Ser-2 phosphorylation, downregulates Mcl-1 and HDM2 expression levels, and induces PARP cleavage in A2780 ovarian cancer cells[1].
CDK9-IN-53 (1.0-10 μM; 8-48 h) strongly induced Caspase-3 activity and apoptosis in primary chronic lymphocytic leukemia (CLL) cells (LD50 = 2.6 μM) and significantly downregulated the expression level of the anti-apoptotic protein Mcl-1[1].
CDK9-IN-53 inhibits CDK9/cyclin T1 with IC50 = 14 nM in in vitro kinase biochemical inhibition assays, and CDK9 Ki = 7 nM has been reported, showing >80-fold selectivity over CDK2[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:A2780 ovarian carcinoma cells
-
Concentration:GI50, 5 x GI50
-
Incubation Time:48 h
-
Result:Induced caspase-dependent apoptosis in a dose-dependent manner (38% at GI50 and 50% at 5 x GI50).
-
Cell Line:A2780 ovarian carcinoma cells
-
Concentration:GI50, 5 x GI50
-
Incubation Time:24 h
-
Result:Caused accumulation of cells in the G2/M phase at the 5 x GI50 concentration.
-
Cell Line:A2780 ovarian carcinoma cells
-
Concentration:GI50, 5 x GI50
-
Incubation Time:24 h
-
Result:Inhibited the phosphorylation of Ser-2 of RNAPII CTD, down-regulated the expression of Mcl-1 and HDM2, and induced PARP cleavage, confirming cellular CDK9 inhibition and apoptosis induction.
Chemical Information
-
CAS No. 1421340-50-2
-
Molecular Weight 420.54
-
Formula C21H24N8S
-
SMILES
N#CC=1C=NC(=NC1C=2SC(=NC2C)NC)NC3=CC=CC(=C3)N4CCNCCC4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)